Olezarsen — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Part
Phase 3 · Severe Hypertriglyceridemia |
IONS IONIS PHARMACEUTICALS INC | Olezarsen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
|